PolTREG raises 100 million pln on Warsaw Stock Exchange to battle diabetes

The Gdańsk-based company PolTREG, which is working on an innovative therapy for the treatment of type I diabetes, has debuted on the Warsaw Stock Exchange. The share price was set at PLN 75.

The final number of shares offered to institutional investors was 1,065,932 shares, to individual investors – 266,482 shares, and the total value of the public offering is PLN 99,931,050.

PolTREG is a company founded by scientists from the Medical University of Gdańsk, who since 2006 have been conducting research on the treatment of type I diabetes in children.

Founded by: prof. Piotr Trzonkowski, prof. Małgorzata Myśliwiec and prof. Natalia Marek-Trzonkowska PolTREG is one of the most innovative biotechnology companies in the world. Develops therapies using T-regulatory lymphocytes (TREGS). These therapies are used in autoimmune diseases, i.e. diseases where the body’s own immune system attacks.

The purpose of the debut on the Warsaw Stock Exchange is to obtain funds necessary to achieve the company’s key strategic goals by the first quarter of 2025. These goals include research and development related to the next stages of research into a therapy for the treatment of type 1 diabetes in children and the treatment of multiple sclerosis that the company is working on, as well as the development of Treg 2.0.


Our privacy policy